Exploring Combination Strategies for the Treatment of Chronic Lymphocytic Leukemia: Oncology Pharmacy Pearls for Optimizing Patient Care

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.

Program Description

Chronic lymphocytic leukemia (CLL) is a common form of leukemia affecting older adults. Treatment modalities focus on prolonging survival and improving patient quality of life. Oral therapies, including Bruton's tyrosine kinase and B-cell lymphoma 2 inhibitors, have allowed for improvements in patient outcomes; however, adherence to therapy is crucial. Pharmacists are heavily involved in therapy selection, adverse effect management, and patient education for those with CLL. This activity will highlight the clinical safety and efficacy data for managing CLL and will also focus on the pharmacist’s role. Additionally, clinical pharmacists will engage in a panel discussion where patient cases will be presented to enforce topics introduced, including treatment selection and adverse effect management.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 15, 2022
Expiration date: April 15, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify challenges associated with current treatment strategies for chronic lymphocytic leukemia (CLL), justifying the continued investigation of combination strategies with a Bruton’s tyrosine kinase inhibitor (BTKi) and/or venetoclax
• Explore safety and efficacy data for doublet and triplet therapeutic approaches for the treatment of CLL
• Construct a plan to optimize care coordination, adherence monitoring, and adverse effect management for patients with CLL receiving combination therapy with a BTKi and/or venetoclax

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-165-H01-P. The activity is available for CE credit through April 15, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Emily Dotson, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant (advisory board): AstraZeneca Pharmaceuticals, BeiGeine, Janssen

Peter Campbell, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Pharmacosmos

Other Support: Advisory Board for IV iron product

Arpita Gandhi, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms